XBiotech Inc. (XBIT) AI Stock Analysis
XBIT AI stock analysis summary
AI ResearchXBiotech Inc. (XBIT) is a biopharmaceutical company focused on developing True Human monoclonal antibodies for inflammatory and infectious diseases. For FY2023, the company reported $300,000 in revenue and a net loss of -$24.6M. However, it holds $109.5M in cash and short-term investments as of June 30, 2026, resulting in a negative enterprise value of -$96.0M.
- Market cap
- $64.6M
- Revenue (TTM)
- $300,000
- P/E
- —
- 1Y return
- -14.9% S&P 500 16.8%
- Avg. target
- $18.00 749.1% vs last close
Bull case
- XBiotech held $109.5M in cash and short-term investments as of June 30, 2026, with an enterprise value of -$96.0M.
- The company exhibits a strong liquidity position with a current ratio of 33.15 as of June 30, 2026.
- Analysts set a mean price target of $18.00, implying a 749.1% upside compared to the last close of $2.12.
Bear case
- Trailing twelve months revenue stood at just $300,000, while quarterly revenue fell 93.3% year-over-year for the period ending June 30, 2026.
- XBiotech generated a net loss of -$24.6M and free cash flow of -$19.1M in FY2023.
- The stock has experienced long-term underperformance, falling 84.0% over 5 years while the S&P 500 gained 83.0%.
What XBiotech does
XBiotech Inc. is an Austin, Texas-based biopharmaceutical company founded in 2005 that specializes in the discovery, development, and commercialization of True Human monoclonal antibodies. The company focuses on inflammatory and infectious diseases, advancing interleukin-1 alpha therapies targeting conditions such as cancer, stroke, heart attack, and arthritis. These therapies address processes including tissue breakdown, angiogenesis, blood clot formation, muscle wasting, malaise, and inflammation. In addition, XBiotech is actively developing a True Human COVID-19 therapy to address mutating strains of the virus.
Growth and profitability
Revenue declined from $44.0M in FY2020 to $18.4M in FY2021, $4.0M in FY2022, and $300,000 in FY2023, reflecting a 4-year revenue CAGR of -60.8%. Operating margin contracted from -41.5% in FY2020 to -12503.3% in FY2023. After recording net income of $668.6M in FY2019, XBiotech posted net losses of -$11.2M in FY2020, -$17.4M in FY2021, -$32.9M in FY2022, and -$24.6M in FY2023. Diluted EPS was -$0.81 in FY2023. Over the trailing twelve months ending June 30, 2026, revenue stood at $300,000, with quarterly revenue falling 93.3% year-over-year and EPS at -$1.48.
Balance sheet and cash flow
As of June 30, 2026, XBiotech held $109.5M in cash and short-term investments, contributing to total assets of $133.7M and shareholders' equity of $128.5M. The company maintains strong liquidity with a current ratio of 33.15. Free cash flow was -$19.1M in FY2023, driven by operating cash flow of -$18.7M. For FY2025, capital expenditures were $289,000, while the company's 5-year share count change was 0.5%.
Valuation and performance
At a market cap of $64.6M and an enterprise value of -$96.0M, XBiotech trades at a price-to-sales ratio of 12.2x and an EV-to-revenue ratio of 24.1x. Its price-to-sales ratio is higher than the 4.1x median of its US-listed Healthcare peers. The company's price-to-book ratio is 0.5x. Over the past year, the stock fell 14.9%, underperforming the S&P 500 return of 16.8%. Over a 5-year period, the stock fell 84.0%, while the S&P 500 gained 83.0%.
What analysts expect
Analysts maintain a mean price target of $18.00 for XBiotech, which sits 749.1% above its last close of $2.12 recorded on October 16, 2026. Looking at its track record, the company registered 0 EPS beats over the last 4 quarters. XBiotech's next earnings report date is scheduled for November 11, 2026, as investors monitor progression toward commercial pipeline milestones.
Key risks and what to watch
- Revenue contracted at a 4-year CAGR of -60.8% between FY2019 and FY2023.
- R&D expense remained high at $32.8M in FY2023, sustaining cash burn and resulting in operating cash flow of -$18.7M.
- The company registered 0 EPS beats over the last 4 quarters, highlighting consistent earnings misses.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this XBIT AI stock analysis
This page is an AI-written research summary of XBiotech Inc. (XBIT). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: XBIT income statement, XBIT balance sheet, XBIT key metrics, XBIT chart. See the XBIT stock overview for the latest quote and news.
XBIT AI stock analysis FAQ
What is XBiotech's current cash position?
As of June 30, 2026, XBiotech reported $109.5M in cash and short-term investments, supporting a current ratio of 33.15.
Does XBiotech pay a dividend?
No, XBiotech does not pay a regular dividend and retains its capital to fund research and pipeline operations.
What is the analyst price target for XBIT?
The mean analyst price target is $18.00, representing a 749.1% premium over the last closing price of $2.12 on October 16, 2026.
What was XBiotech's revenue in the most recent fiscal year?
In FY2023, XBiotech generated $300,000 in revenue, down from $4.0M in FY2022 and $18.4M in FY2021.